VCM
TVTX icon

Voleon Capital Management’s Travere Therapeutics TVTX Stock Holding History

Voleon Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.29M Sell
43,355
-59,198
-58% -$1.77M 0.03% 400
2025
Q4 		$3.92M Buy
+102,553
New +$3.33M 0.08% 230

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Voleon Capital Management's TVTX Position: Q1 2026 in Review

Voleon Capital Management reduced its Travere Therapeutics (TVTX) stake by 58% in Q1 2026, selling an estimated $1.77M and leaving 43,355 shares worth $1.29M. The position accounts for 0.03% of the portfolio, ranked #400.

Voleon Capital Management first reported a position in TVTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $3.92M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Voleon Capital Management held 43,355 shares of Travere Therapeutics worth $1.29M as of Q1 2026.
  • Voleon Capital Management sold 59,198 Travere Therapeutics shares in Q1 2026, an estimated $1.77M.
  • Travere Therapeutics made up 0.03% of Voleon Capital Management's portfolio in Q1 2026, its #400 holding.
  • Voleon Capital Management first reported a position in Travere Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Voleon Capital Management's Travere Therapeutics position peaked at $3.92M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Voleon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.